Activities of factor V and VIII after mpHHP treatment (200/250 Mpa, 5 cycles of 1min) at near 0°C temperature, n = 3.

<p>Activities of factor V and VIII after mpHHP treatment (200/250 Mpa, 5 cycles of 1min) at near 0°C temperature, n = 3.</p

Activities of coagulation factors after optimized HHP treatment (200/250 Mpa, 5 cycles of 1min, at near 0°C temperature), n = 3.

<p>Activities of coagulation factors after optimized HHP treatment (200/250 Mpa, 5 cycles of 1min, at near 0°C temperature), n = 3.</p

Kinetics of bacterium inactivation by optimized HHP treatment (200/250 Mpa, 5 cycles of 1min, at near 0°C temperature), n = 3.

<p>Kinetics of bacterium inactivation by optimized HHP treatment (200/250 Mpa, 5 cycles of 1min, at near 0°C temperature), n = 3.</p

Inactivation of <i>E</i>.<i>coli</i> under two mpHHP modes (200/250 Mpa, 5 cycles of 1min) at low temperature (near 0°C) and room temperature, n = 3.

<p>Inactivation of <i>E</i>.<i>coli</i> under two mpHHP modes (200/250 Mpa, 5 cycles of 1min) at low temperature (near 0°C) and room temperature, n = 3.</p

Inactivation of <i>E</i>.<i>coli</i> under mpHHP (5 cycles of 1 min) and spHHP (1 cycle of 5 min) application modes with escalated pressure, n = 3.

<p>Inactivation of <i>E</i>.<i>coli</i> under mpHHP (5 cycles of 1 min) and spHHP (1 cycle of 5 min) application modes with escalated pressure, n = 3.</p

The content of plasma proteins after HHP treatment (200/250 Mpa, 5 cycles of 1min, at near 0°C temperature), n = 3, mean±SD.

<p>The content of plasma proteins after HHP treatment (200/250 Mpa, 5 cycles of 1min, at near 0°C temperature), n = 3, mean±SD.</p

Change of activities of coagulation factor V and VIII under mpHHP treatments (5 cycles of 1 min) with escalated pressure (≥ 300MPa), n = 3.

<p>Change of activities of coagulation factor V and VIII under mpHHP treatments (5 cycles of 1 min) with escalated pressure (≥ 300MPa), n = 3.</p

Phylogenic tree of the HIV-1 sequences.

<p>Phylogenic tree of the HIV-1 sequences.</p

Demographic characteristics and subtypes of 205 infected donors whose HIV genotypes and DRMs were successfully analyzed.

<p>Demographic characteristics and subtypes of 205 infected donors whose HIV genotypes and DRMs were successfully analyzed.</p

Summary of HIV testing and DRMs analysis among blood donors from five Chinese blood centers, April 2012 to June 2014.

<p>Summary of HIV testing and DRMs analysis among blood donors from five Chinese blood centers, April 2012 to June 2014.</p